Identification

Name
Miconazole
Accession Number
DB01110  (APRD01115)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

An imidazole antifungal agent that is used topically and by intravenous infusion. [PubChem]

Structure
Thumb
Synonyms
  • 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
  • 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
  • Daktarin iv
  • Miconazole
  • Monistat iv (tn)
Product Ingredients
IngredientUNIICASInChI Key
Miconazole nitrateVW4H1CYW1K22832-87-7MCCACAIVAXEFAL-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OravigTablet50 mg/1BuccalPraelia Pharmaceuticals Inc2012-11-012015-12-29Us
OravigTablet50 mg/1BuccalMidatech Pharma Us, Inc.2010-04-16Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Miconazole NitrateSuppository200 mg/1VaginalActavis Pharma Company2002-09-03Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
3M Cavilon AntifungalCream2 g/1000gTopical3 M Pharmaceuticals2010-11-30Not applicableUs
7 Day VaginalCream2 g/100gTopicalCardinal Health2009-03-16Not applicableUs
Aloe Vesta AntifungalOintment20 mg/gTopicalConvatec Inc.1997-10-03Not applicableUs
Aloe Vesta Clear AntifungalOintment2 g/100gTopicalConvatec Inc.2013-12-20Not applicableUs
Aloe Vesta Clear Antifungal 141gOintment2.82 g/141gTopicalGuest Packaging Llc.2016-06-09Not applicableUs
Aloe Vesta Clear Antifungal 56gOintment1.12 g/56gTopicalGuest Packaging Llc.2016-06-09Not applicableUs
Anti-FungalCream.02 g/gTopicalUniversal Distribution Center LLC2015-04-15Not applicableUs
AntifungalCream2 mg/100mLTopicalMc Kesson2017-05-26Not applicableUs
AntifungalCream20 mg/gTopicalActavis Pharma Company2007-05-01Not applicableUs
AntifungalCream20 mg/gTopicalA S Medication Solutions2007-05-012017-06-20Us
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Miconazole NitrateCream20 mg/gVaginalRemedy Repack2017-10-31Not applicableUs
Miconazole NitrateAerosol, spray1.3 g/130gTopicalAmerican Sales Company2017-10-20Not applicableUs
Miconazole NitratePowder1.42 g/71gTopicalPremier Brands of America Inc.2017-04-03Not applicableUs
Miconazole NitrateAerosol, powder2.6 g/130gTopicalFoodhold Usa2017-10-20Not applicableUs
Miconazole NitrateAerosol, spray1.3 g/130gTopicalPremier Brands Of America Inc2017-06-10Not applicableUs
International/Other Brands
Daktarin / Decocort / Femizol-M / Gyno-Daktarin / Miconazex / Monistat / Monistat-Derm / Zeasorb-AF / Zimycan
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DermaSanaMiconazole nitrate (200 mg/mg) + Triclosan (30 mg/mg)CreamTopicalOmg Medical Group, Llc2013-02-14Not applicableUs
Monicure ComboMiconazole nitrate (2 %) + Fluconazole (150 mg)Capsule; Cream; KitOral; TopicalInsight Pharmaceuticals2012-10-25Not applicableCanada
Monistat 1 Combination PackMiconazole nitrate (1200 mg) + Miconazole nitrate (2 %)Cream; SuppositoryTopical; VaginalInsight Pharmaceuticals1999-02-26Not applicableCanada
Monistat 1 Combination PackMiconazole nitrate (1200 mg) + Miconazole nitrate (2 %)Cream; SuppositoryTopical; VaginalInsight Pharmaceuticals1999-02-26Not applicableCanada
Monistat 3 Dual-pakMiconazole nitrate (2 %) + Miconazole nitrate (400 mg)Cream; InsertTopical; VaginalInsight Pharmaceuticals1986-12-31Not applicableCanada
Monistat 3 Dual-pakMiconazole nitrate (2 %) + Miconazole nitrate (400 mg)Cream; InsertTopical; VaginalInsight Pharmaceuticals1986-12-31Not applicableCanada
Monistat 7 Dual-pakMiconazole nitrate (100 mg) + Miconazole nitrate (2 %)Cream; SuppositoryTopical; VaginalInsight Pharmaceuticals1994-12-31Not applicableCanada
Monistat 7 Dual-pakMiconazole nitrate (100 mg) + Miconazole nitrate (2 %)Cream; SuppositoryTopical; VaginalInsight Pharmaceuticals1994-12-31Not applicableCanada
Rash Relief AntifungalMiconazole nitrate (2 g/100g) + Dimethicone (10 g/100g) + Zinc oxide (10 g/100g)LiquidTopicalTouchless Care Concepts LLC2006-06-14Not applicableUs
VusionMiconazole nitrate (2.5 mg/g) + Petrolatum (813.5 mg/g) + Zinc oxide (150 mg/g)OintmentTopicalPrestium Pharma, Inc.2007-05-14Not applicableUs
Categories
UNII
7NNO0D7S5M
CAS number
22916-47-8
Weight
Average: 416.129
Monoisotopic: 413.986023908
Chemical Formula
C18H14Cl4N2O
InChI Key
BYBLEWFAAKGYCD-UHFFFAOYSA-N
InChI
InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
IUPAC Name
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
SMILES
ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1

Pharmacology

Indication

For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.

Structured Indications
Pharmacodynamics

Miconazole is an anti-fungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). It is used either on the skin or in the vagina for fungal infections. Miconazole was approved by the FDA in 1974. Miconazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections.

Mechanism of action

Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

TargetActionsOrganism
ALanosterol 14-alpha demethylase
inhibitor
Yeast
UNitric oxide synthase, endothelial
inhibitor
Human
UNitric oxide synthase, inducible
inhibitor
Human
UCalcium-activated potassium channel subunit alpha-1
inhibitor
Human
UCalcium-activated potassium channel subunit beta-1
inhibitor
Human
UCalcium-activated potassium channel subunit beta-2
inhibitor
Human
UCalcium-activated potassium channel subunit beta-3
inhibitor
Human
UCalcium-activated potassium channel subunit beta-4
inhibitor
Human
UIntermediate conductance calcium-activated potassium channel protein 4
inhibitor
Human
USmall conductance calcium-activated potassium channel protein 1
inhibitor
Human
USmall conductance calcium-activated potassium channel protein 2
inhibitor
Human
USmall conductance calcium-activated potassium channel protein 3
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 6
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 7
inhibitor
Human
UNuclear receptor subfamily 1 group I member 2
partial agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 3800 mg/kg; Oral, rat: LD50 = 3 gm/kg. Ingestion of the amounts of the components contained in a tube of cream are unlikely to produce overdosage and toxic effects.

Affected organisms
  • Fungi, yeast and protozoans
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Miconazole.Approved
AcetohexamideMiconazole may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Miconazole.Approved
AmiodaroneThe metabolism of Miconazole can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Miconazole is combined with Amrinone.Approved
AprepitantThe serum concentration of Miconazole can be increased when it is combined with Aprepitant.Approved, Investigational
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Miconazole resulting in a loss in efficacy.Approved, Investigational
AtazanavirThe metabolism of Miconazole can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Miconazole can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Miconazole is combined with Atorvastatin.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Miconazole is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Barnidipine.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Miconazole is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Miconazole is combined with Bepridil.Approved, Withdrawn
BoceprevirThe metabolism of Miconazole can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Miconazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Miconazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Miconazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Miconazole.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Miconazole.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Miconazole.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Miconazole.Approved, Investigational
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Miconazole.Approved
CarbamazepineThe metabolism of Miconazole can be increased when combined with Carbamazepine.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Carboxyamidotriazole.Investigational
CarbutamideMiconazole may increase the hypoglycemic activities of Carbutamide.Experimental
CaroverineThe risk or severity of adverse effects can be increased when Miconazole is combined with Caroverine.Experimental
CeritinibThe serum concentration of Miconazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Miconazole.Withdrawn
ChlorpropamideMiconazole may increase the hypoglycemic activities of Chlorpropamide.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Cilnidipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Miconazole.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Miconazole is combined with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Miconazole.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Miconazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Miconazole can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Clevidipine.Approved
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Miconazole.Experimental
ClotrimazoleThe metabolism of Miconazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Miconazole can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Miconazole.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Miconazole.Approved, Investigational
CrizotinibThe metabolism of Miconazole can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Miconazole.Approved
DabrafenibThe serum concentration of Miconazole can be decreased when it is combined with Dabrafenib.Approved
DarodipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Darodipine.Experimental
DarunavirThe metabolism of Miconazole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Miconazole can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Miconazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Miconazole can be decreased when combined with Delavirdine.Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Miconazole.Approved
DidanosineDidanosine can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Miconazole.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Miconazole.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Miconazole.Experimental
DihydroergotamineThe metabolism of Miconazole can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Miconazole is combined with Diltiazem.Approved
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Miconazole.Experimental
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Miconazole.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Miconazole.Approved
DotarizineThe risk or severity of adverse effects can be increased when Miconazole is combined with Dotarizine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Miconazole.Approved, Investigational
DoxycyclineThe metabolism of Miconazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Miconazole can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Miconazole.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Efonidipine.Approved, Investigational
EnzalutamideThe serum concentration of Miconazole can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Miconazole is combined with Eperisone.Approved, Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Miconazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Miconazole.Approved
ErythromycinThe metabolism of Miconazole can be decreased when combined with Erythromycin.Approved, Vet Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Miconazole.Withdrawn
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Miconazole.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Miconazole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Miconazole is combined with Fendiline.Withdrawn
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole.Approved
FluconazoleThe metabolism of Miconazole can be decreased when combined with Fluconazole.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Miconazole.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Miconazole is combined with Flunarizine.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Miconazole.Approved
FluvoxamineThe metabolism of Miconazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Miconazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Miconazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Miconazole.Approved
Fusidic AcidThe serum concentration of Miconazole can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Miconazole is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Miconazole is combined with Gallopamil.Investigational
GlibornurideMiconazole may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideMiconazole may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMiconazole may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMiconazole may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneMiconazole may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideMiconazole may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideMiconazole may increase the hypoglycemic activities of Glyburide.Approved
ImatinibThe metabolism of Miconazole can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Miconazole can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Miconazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Isradipine.Approved
ItraconazoleThe metabolism of Miconazole can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Miconazole can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Miconazole can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Miconazole is combined with Lamotrigine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Miconazole.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Lercanidipine.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Miconazole is combined with Lidoflazine.Experimental
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Miconazole.Approved, Investigational
LopinavirThe metabolism of Miconazole can be decreased when combined with Lopinavir.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Miconazole.Approved
LovastatinThe metabolism of Miconazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Miconazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Miconazole can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Miconazole.Illicit, Investigational, Withdrawn
Magnesium SulfateThe risk or severity of adverse effects can be increased when Miconazole is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Manidipine.Approved, Investigational
MetahexamideMiconazole may increase the hypoglycemic activities of Metahexamide.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Miconazole.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Miconazole.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Miconazole.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Miconazole.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Miconazole.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Miconazole is combined with Mibefradil.Investigational, Withdrawn
MifepristoneThe serum concentration of Miconazole can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Miconazole can be decreased when it is combined with Mitotane.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Miconazole is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Miconazole.Approved
NefazodoneThe metabolism of Miconazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Miconazole can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Miconazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Miconazole can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Miconazole.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Niguldipine.Experimental
NilotinibThe metabolism of Miconazole can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Miconazole is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Miconazole.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Miconazole is combined with Nitrendipine.Approved, Investigational
OlaparibThe metabolism of Miconazole can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Miconazole can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Miconazole is combined with Otilonium.Experimental, Investigational
PalbociclibThe serum concentration of Miconazole can be increased when it is combined with Palbociclib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Miconazole.Approved
PentobarbitalThe metabolism of Miconazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Miconazole.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Miconazole is combined with Perhexiline.Approved, Investigational
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Miconazole.Approved, Investigational
PhenobarbitalThe metabolism of Miconazole can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Miconazole.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Miconazole.Approved, Vet Approved
PimozideMiconazole may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Miconazole is combined with Pinaverium.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Miconazole.Approved
PosaconazoleThe metabolism of Miconazole can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Miconazole.Approved
PregabalinThe risk or severity of adverse effects can be increased when Miconazole is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Miconazole is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Miconazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Miconazole.Approved, Vet Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Miconazole.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Miconazole.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Miconazole.Approved, Investigational
RifabutinThe metabolism of Miconazole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Miconazole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Miconazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Miconazole.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Miconazole is combined with Risedronate.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Miconazole.Approved
SaquinavirThe metabolism of Miconazole can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Miconazole can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Miconazole.Approved
SiltuximabThe serum concentration of Miconazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Miconazole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Miconazole.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Miconazole.Approved
St. John's WortThe serum concentration of Miconazole can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Miconazole can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfisoxazoleThe metabolism of Miconazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Miconazole.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Miconazole.Approved, Investigational
TelaprevirThe metabolism of Miconazole can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Miconazole can be decreased when combined with Telithromycin.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Miconazole.Experimental
TerodilineThe risk or severity of adverse effects can be increased when Miconazole is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Miconazole is combined with Tetrahydropalmatine.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Miconazole.Approved, Withdrawn
TiclopidineThe metabolism of Miconazole can be decreased when combined with Ticlopidine.Approved
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Miconazole.Experimental
TocilizumabThe serum concentration of Miconazole can be decreased when it is combined with Tocilizumab.Approved
TolazamideMiconazole may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideMiconazole may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Miconazole is combined with Tolfenamic Acid.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Miconazole.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Miconazole is combined with Tranilast.Approved, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Miconazole.Approved, Investigational, Nutraceutical
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Miconazole.Approved
VenlafaxineThe metabolism of Miconazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Miconazole is combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Miconazole.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Miconazole is combined with Vinpocetine.Investigational
VoriconazoleThe metabolism of Miconazole can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Miconazole.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Miconazole is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Miconazole is combined with Ziconotide.Approved
ZiprasidoneThe metabolism of Miconazole can be decreased when combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Miconazole.Approved
Food Interactions
Not Available

References

Synthesis Reference
US3717655
General References
Not Available
External Links
Human Metabolome Database
HMDB15242
KEGG Drug
D00882
KEGG Compound
C08070
PubChem Compound
4189
PubChem Substance
46506017
ChemSpider
4044
BindingDB
31772
ChEBI
82892
ChEMBL
CHEMBL91
Therapeutic Targets Database
DAP000154
PharmGKB
PA450494
IUPHAR
2449
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Miconazole
ATC Codes
A01AB09 — MiconazoleD01AC02 — MiconazoleA07AC01 — MiconazoleJ02AB01 — MiconazoleS02AA13 — MiconazoleG01AF04 — MiconazoleD01AC52 — Miconazole, combinations
AHFS Codes
  • 84:04.08.08 — Azoles
FDA label
Download (650 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentIntertrigo1
1CompletedDiagnosticEndometriosis1
1CompletedPreventionHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentAutoimmune Diseases / Disseminated or Multiple Sclerosis Nos / Disseminated Sclerosis / Multiple Sclerosis, Acute Relapsing / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis, Primary Progressive1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentTinea Cruris1
2, 3Not Yet RecruitingTreatmentInfections, Fungal1
2, 3Not Yet RecruitingTreatmentCandidiasis infection1
3CompletedTreatmentOral Candidiasis / Stomatitis, Denture1
4CompletedNot AvailableHealth / Vulvovaginal Candidiasis1
4CompletedTreatmentDiaper Rash1
4RecruitingTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
4Unknown StatusTreatmentMelasma1
4Unknown StatusTreatmentOnychomycosis1
Not AvailableCompletedNot AvailableBacterial Vaginosis (BV) / Trichomonal Vaginitis / Vaginal Candidiasis1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableUnknown StatusTreatmentOnychomycosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
OintmentTopical20 mg/g
OintmentTopical2.82 g/141g
OintmentTopical1.12 g/56g
CreamTopical2 mg/100mL
CreamTopical2 g/1000g
PowderTopical2 g/100mL
TinctureTopical20 mg/mL
CreamTopical.02 g/g
SprayTopical20 mg/g
CreamTopical.02 g/100g
CreamTopical
CreamTopical20 g/1000g
SprayTopical2 g/100g
Kit
CreamTopical2 g/100g
CreamTopical20 mg/mL
Aerosol, sprayTopical.2 g/10g
CreamTopical20 mg/g
PowderTopical1.42 g/71g
Aerosol, powderTopical20 mg/g
LiquidTopical2 g/100g
CreamTopical2 %
AerosolTopical2 %
KitTopical; Vaginal
KitVaginal
SuppositoryVaginal400 mg
CreamVaginal2 mg/100g
CreamVaginal2 g/100g
SuppositoryVaginal100 mg/1
Aerosol, powderTopical2.6 g/130g
Aerosol, sprayTopical1.3 g/131g
Aerosol, sprayTopical1.3 g/130g
Aerosol, sprayTopical2.6 g/130g
Aerosol, sprayTopical3 g/150g
CreamVaginal20 mg/g
PowderTopical2.6 g/130g
SprayTopical3 g/150g
SuppositoryVaginal100 ug/1
SuppositoryVaginal200 mg/1
PowderTopical20 mg/g
CreamTopical.3 g/14g
CreamVaginal20 mg
Capsule; cream; kitOral; Topical
SuppositoryVaginal1200 mg
Cream; insertTopical; Vaginal
CreamVaginal4 %
InsertVaginal400 mg
Cream; suppositoryTopical; Vaginal
SuppositoryVaginal100 mg
CreamVaginal2 %
CreamTopical200 mg/mg
CreamTopical.02 mL/mL
TabletBuccal50 mg/1
LiquidTopical
PowderTopical2 g/100g
CreamTopical20 mg/100g
Kit
CreamTopical.7 g/35g
Aerosol, powderTopical2.56 g/128g
CreamVaginal40 mg/g
LiquidTopical.3 mg/15mL
OintmentTopical
OintmentTopical2 g/100g
PowderTopical20.6 mg/g
Prices
Unit descriptionCostUnit
Vusion 0.25-15-81.35% Ointment 50 gm Tube284.34USD tube
Miconazole 3 3 200 mg Suppository Box51.2USD box
Monistat-Derm 2% Cream 28.35 gm Tube41.99USD tube
Monistat-Derm 2% Cream 15 gm Tube32.0USD tube
Monistat 1 combination pack16.81USD each
Monistat 7 combination pack15.96USD each
Miconazole Nitrate 2% Cream 28 gm Tube12.99USD tube
Miconazole powder4.59USD g
Monistat 1 6.5% ointment3.6USD g
Miconazole nitrate powder3.55USD g
Vusion ointment3.17USD g
Monistat-derm 2% cream1.11USD g
Miconazole nitrate 2% cream0.19USD g
CVS Pharmacy miconazole 7 cream0.18USD g
Miconazole 7 cream0.15USD g
Antifungal 2% cream0.1USD g
Micatin 2% aerosol spray0.05USD g
Lotrimin af 2% liquid spray0.04USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5514698No1994-03-212014-03-21Us
US8147852No2008-03-302028-03-30Us
US6153635No2000-11-282020-11-28Us
US6916485No2002-09-112022-09-11Us
US7651698No2002-09-112022-09-11Us
US8518442No2002-09-112022-09-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)159-163 °CNot Available
water solubility1g/100mL (20 °C)Not Available
logP6.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000763 mg/mLALOGPS
logP5.86ALOGPS
logP5.96ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)6.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area27.05 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.07 m3·mol-1ChemAxon
Polarizability39.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9735
Blood Brain Barrier+0.9823
Caco-2 permeable+0.6096
P-glycoprotein substrateNon-substrate0.545
P-glycoprotein inhibitor INon-inhibitor0.7958
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6806
CYP450 2C9 substrateNon-substrate0.8407
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7017
CYP450 1A2 substrateInhibitor0.9472
CYP450 2C9 inhibitorInhibitor0.939
CYP450 2D6 inhibitorInhibitor0.9413
CYP450 2C19 inhibitorInhibitor0.9591
CYP450 3A4 inhibitorInhibitor0.8861
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9961
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.853
BiodegradationNot ready biodegradable0.9933
Rat acute toxicity2.8478 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.8505
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0bt9-4900000000-3f143064c2acde7e15a4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02t9-0501900000-40f5928152d84e02deef
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0bt9-2900000000-1921b08c2de7bbf0624d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0bt9-0900500000-1a5805da9606edbe7e9a

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzylethers
Direct Parent
Benzylethers
Alternative Parents
Dichlorobenzenes / N-substituted imidazoles / Aryl chlorides / Heteroaromatic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Benzylether / 1,3-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / N-substituted imidazole / Imidazole / Azole / Heteroaromatic compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, ether, dichlorobenzene (CHEBI:82892) / a small molecule (CPD-4501)

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sterol 14-demethylase activity
Specific Function
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name
ERG11
Uniprot ID
P10613
Uniprot Name
Lanosterol 14-alpha demethylase
Molecular Weight
60674.965 Da
References
  1. White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998 Apr;11(2):382-402. [PubMed:9564569]
  2. Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999 Oct;12(4):501-17. [PubMed:10515900]
  3. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848]
  4. Georgopapadakou NH, Walsh TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 1996 Feb;40(2):279-91. [PubMed:8834867]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
Gene Name
NOS3
Uniprot ID
P29474
Uniprot Name
Nitric oxide synthase, endothelial
Molecular Weight
133287.62 Da
References
  1. Wolff DJ, Datto GA, Samatovicz RA: The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents. J Biol Chem. 1993 May 5;268(13):9430-6. [PubMed:7683652]
  2. Bogle RG, Whitley GS, Soo SC, Johnstone AP, Vallance P: Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol. 1994 Apr;111(4):1257-61. [PubMed:7518297]
  3. Sennequier N, Wolan D, Stuehr DJ: Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem. 1999 Jan 8;274(2):930-8. [PubMed:9873034]
  4. Dudek RR, Conforto A, Pinto V, Wildhirt S, Suzuki H: Inhibition of endothelial nitric oxide synthase by cytochrome P-450 reductase inhibitors. Proc Soc Exp Biol Med. 1995 May;209(1):60-4. [PubMed:7536941]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
Gene Name
NOS2
Uniprot ID
P35228
Uniprot Name
Nitric oxide synthase, inducible
Molecular Weight
131116.3 Da
References
  1. Wolff DJ, Datto GA, Samatovicz RA: The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents. J Biol Chem. 1993 May 5;268(13):9430-6. [PubMed:7683652]
  2. Bogle RG, Whitley GS, Soo SC, Johnstone AP, Vallance P: Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol. 1994 Apr;111(4):1257-61. [PubMed:7518297]
  3. Sennequier N, Wolan D, Stuehr DJ: Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem. 1999 Jan 8;274(2):930-8. [PubMed:9873034]
  4. Dudek RR, Conforto A, Pinto V, Wildhirt S, Suzuki H: Inhibition of endothelial nitric oxide synthase by cytochrome P-450 reductase inhibitors. Proc Soc Exp Biol Med. 1995 May;209(1):60-4. [PubMed:7536941]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium channel regulator activity
Specific Function
Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Incr...
Gene Name
KCNMB1
Uniprot ID
Q16558
Uniprot Name
Calcium-activated potassium channel subunit beta-1
Molecular Weight
21797.27 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium channel regulator activity
Specific Function
Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Acts...
Gene Name
KCNMB2
Uniprot ID
Q9Y691
Uniprot Name
Calcium-activated potassium channel subunit beta-2
Molecular Weight
27129.37 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium channel regulator activity
Specific Function
Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Alte...
Gene Name
KCNMB3
Uniprot ID
Q9NPA1
Uniprot Name
Calcium-activated potassium channel subunit beta-3
Molecular Weight
31603.26 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium channel regulator activity
Specific Function
Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Decr...
Gene Name
KCNMB4
Uniprot ID
Q86W47
Uniprot Name
Calcium-activated potassium channel subunit beta-4
Molecular Weight
23948.465 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein phosphatase binding
Specific Function
Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Requi...
Gene Name
KCNN4
Uniprot ID
O15554
Uniprot Name
Intermediate conductance calcium-activated potassium channel protein 4
Molecular Weight
47695.12 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Small conductance calcium-activated potassium channel activity
Specific Function
Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
Gene Name
KCNN1
Uniprot ID
Q92952
Uniprot Name
Small conductance calcium-activated potassium channel protein 1
Molecular Weight
59986.87 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Small conductance calcium-activated potassium channel activity
Specific Function
Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
Gene Name
KCNN2
Uniprot ID
Q9H2S1
Uniprot Name
Small conductance calcium-activated potassium channel protein 2
Molecular Weight
63759.03 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Small conductance calcium-activated potassium channel activity
Specific Function
Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
Gene Name
KCNN3
Uniprot ID
Q9UGI6
Uniprot Name
Small conductance calcium-activated potassium channel protein 3
Molecular Weight
82025.305 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH6
Uniprot ID
Q9H252
Uniprot Name
Potassium voltage-gated channel subfamily H member 6
Molecular Weight
109923.705 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH7
Uniprot ID
Q9NS40
Uniprot Name
Potassium voltage-gated channel subfamily H member 7
Molecular Weight
134998.525 Da
References
  1. Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
  2. Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P: Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48. Epub 2007 Nov 12. [PubMed:17998298]

Enzymes

Details
1. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
3. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. [PubMed:15969931]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
5. Cytochrome P450 19A1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
  2. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  3. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18